Sp1054
CRC EPIDEMIOLOGY AND DIETS
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
The impact of diets on GI cancers has been well documented, however just recently we are understanding how diet impacts tumorigenesis. This session will provide recent work highlighting the precise mechanism by which diet can alter cancer survival, proliferation, progression, and treatment response of GI Cancers. Moreover, we will complement the mechanistic work in this area by epidemiologic studies that provide evidence for the effects of diet on cancer risk.
The impact of diets on GI cancers has been well documented, however just recently we are understanding how diet impacts tumorigenesis. This session will provide recent work highlighting the precise mechanism by which diet can alter cancer survival, proliferation, progression, and treatment response of GI Cancers. Moreover, we will complement the mechanistic work in this area by epidemiologic studies that provide evidence for the effects of diet on cancer risk.
Presenter
Washington University
Tracks
Related Products
INTERACTIONS BETWEEN HOST DIETARY INTAKE AND GUT MICROBIAL TRANSCRIPTION IN INFLAMMATORY BOWEL DISEASE
The microbiome plays a central role in intestinal inflammation in IBD. It is influenced by environmental factors included diet…
PREGNANCY AND NEONATAL OUTCOMES AMONG EARLY-ONSET COLORECTAL CANCER SURVIVORS: A NATIONWIDE STUDY
Early-onset colorectal cancer (CRC diagnosed before age 50) has risen worldwide, with an increasing number of survivors of reproductive age. We aimed to investigate the risk of adverse pregnancy and neonatal outcomes among early-onset CRC survivors…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
